When does Daiichi Sankyo report earnings and how could it move 4568.T stock?

Daiichi Sankyo reports on 30 Jan 2026. Earnings, revenue guidance, and pipeline updates—especially for oncology assets—could drive intraday swings and shift analyst forecasts for 4568.T stock.

What are the key valuation metrics for 4568.T stock?

Daiichi Sankyo trades at **PE 20.37** with **EPS 149.45** and market cap **JPY 5.63T**. Price-to-sales is **2.85** and book value per share is **JPY 892.84**, useful for relative valuation.

What does Meyka AI forecast for 4568.T stock?

Meyka AI's forecast model projects **monthly JPY 3,006.66** and **yearly JPY 4,335.16**, implying near-term upside **2.46%** and 12-month upside **47.73%** versus current price. Forecasts are projections, not guarantees.

What are the main risks to consider for 4568.T stock?

Main risks include disappointing trial results, weaker guidance, pricing or reimbursement setbacks, and FX swings that affect reported revenue and margins for the JPX-listed stock.

JP Stocks

Daiichi Sankyo (4568.T JPX) down 5.95% intraday 28 Jan 2026: earnings Jan 30 may reset outlook

ByDanny Kontos January 28, 2026

The 4568.T stock fell to JPY 2,934.50 intraday on 28 Jan 2026, down 185.50 JPY (-5.95%) as traders priced in results due on 30 Jan 2026. The drop followed heavy volume of 7,444,300 shares and wider healthcare sector moves. Daiichi Sankyo (4568.T) trades on the JPX with EPS 149.45 and PE 20.37, below the sector average PE of 23.45. With an upcoming earnings announcement, investors should weigh revenue growth versus research spend and global oncology demand, and track guidance changes that could drive short-term volatility